Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OBI-201
- Development stage
- Preclinical
- Lead developer
- OBI Pharma
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
OBI-201 is a preclinical-stage bispecific antibody-drug conjugate (ADC) developed by OBI Pharmaceuticals that simultaneously targets TROP2 and HER2. It is constructed using OBI's proprietary GlycOBI® platform, which utilizes the dual-function enzyme EndoSymeOBI® and the HYPrOBI® linker to conjugate a topoisomerase I inhibitor payload. By targeting two distinct tumor-associated antigens, OBI-201 is designed to overcome tumor heterogeneity and low antigen expression, potentially improving binding avidity and payload delivery while reducing off-target toxicity. In preclinical models of drug-resistant breast cancer with low HER2 expression, OBI-201 demonstrated superior anti-tumor activity compared to single-target ADCs.
- Other names
- TROP2 x HER2 bispecific ADCTROP-2 x HER2 bispecific ADCTROP 2 x HER2 bispecific ADC
02
Targets
TACSTD2 (Tumor-associated calcium signal transducer 2)TOP1 (DNA Topoisomerase I)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on OBI-201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OBI-201.